Comparative Pharmacology
Head-to-head clinical analysis: KISQALI versus RIBOCICLIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KISQALI versus RIBOCICLIB.
KISQALI vs RIBOCICLIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Kisqali (ribociclib) selectively inhibits CDK4 and CDK6, which are involved in cell cycle progression. By inhibiting these kinases, it reduces retinoblastoma protein (Rb) phosphorylation, leading to cell cycle arrest in the G1 phase and reduced proliferation of cancer cells.
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Selectively inhibits CDK4 and CDK6, leading to reduced phosphorylation of retinoblastoma protein, G1-to-S phase cell cycle arrest, and decreased proliferation of estrogen receptor-positive breast cancer cells.
600 mg orally once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle), in combination with an aromatase inhibitor or fulvestrant.
600 mg orally once daily for 21 consecutive days followed by 7 days off treatment, in combination with an aromatase inhibitor or fulvestrant.
None Documented
None Documented
Clinical Note
moderateRibociclib + Gatifloxacin
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Gatifloxacin."
Clinical Note
moderateRibociclib + Levofloxacin
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Levofloxacin."
Clinical Note
moderateRibociclib + Sparfloxacin
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Sparfloxacin."
Clinical Note
moderateRibociclib + Haloperidol
Terminal half-life is approximately 32 hours (range 29-40 hours) after oral administration, supporting once-daily dosing. The long half-life allows for steady-state achievement within 8 days.
Terminal elimination half-life is 32.0 hours (range 29.2–40.4 hours), supporting once-daily dosing.
Primarily hepatic metabolism via CYP3A4, with 69% of dose eliminated in feces (as unchanged drug and metabolites) and 23% in urine (mostly as metabolites). Unchanged ribociclib accounts for <10% of excreted drug.
Primarily hepatic metabolism (CYP3A4) with fecal excretion as major route (69% of dose as metabolites, 23% unchanged in feces); renal excretion accounts for approximately 12% (primarily as metabolites, <1% unchanged).
Category C
Category C
CDK4/6 Inhibitor Antineoplastic
CDK4/6 Inhibitor
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Haloperidol."